Acelyrin (SLRN) Set to Announce Quarterly Earnings on Wednesday

Acelyrin (NASDAQ:SLRN) will be posting its quarterly earnings results after the market closes on Wednesday, November 13th. Analysts expect Acelyrin to post earnings of ($0.84) per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Acelyrin (NASDAQ:SLRN) last posted its earnings results on Tuesday, August 13th. The company reported ($0.86) EPS for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.08). During the same period last year, the company earned ($0.56) EPS. On average, analysts expect Acelyrin to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Acelyrin Trading Up 2.7 %

Shares of SLRN opened at $6.06 on Tuesday. The firm has a fifty day simple moving average of $5.31 and a two-hundred day simple moving average of $4.98. The firm has a market cap of $604.85 million, a PE ratio of -2.10 and a beta of 1.98. Acelyrin has a 1-year low of $3.36 and a 1-year high of $9.25.

Wall Street Analyst Weigh In

SLRN has been the topic of a number of recent research reports. HC Wainwright downgraded Acelyrin from a “buy” rating to a “neutral” rating and lowered their target price for the company from $18.00 to $6.00 in a report on Wednesday, August 14th. Piper Sandler dropped their price objective on shares of Acelyrin from $68.00 to $20.00 and set an “overweight” rating on the stock in a report on Wednesday, August 14th. Wells Fargo & Company boosted their target price on shares of Acelyrin from $13.00 to $15.00 and gave the company an “overweight” rating in a research report on Wednesday, October 16th. Finally, Morgan Stanley decreased their price target on shares of Acelyrin from $13.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Monday, August 19th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, Acelyrin presently has an average rating of “Moderate Buy” and a consensus target price of $11.17.

About Acelyrin

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.